Fig. 5From: Targeting KRAS mutant cancers: from druggable therapy to drug resistanceAdaptive responses to KRAS (G12C) inhibitors in epithelial and mesenchymal cells. a Inducing epithelial-to-mesenchymal transition (EMT) and cell growth in epithelial cell type. b FGFR1/AXL signaling in the mesenchymal cell typeBack to article page